경보제약

214390KOSPI기초 의약물질 제조업

42.0 / 100

Reference Date: 2026-06-10

Financial Score16.5 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 18.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongbo Pharm, established in 1987, is a specialty pharmaceutical company specializing in raw material drugs, selling cardiovascular medications, inhalation anesthetics, and general pharmaceuticals. With raw material pharmaceuticals revenue at 137.3 billion KRW and finished pharmaceuticals at 96.8 billion KRW in 2024, the company is preparing to enter the global ADC CDMO market through self-developed technology. It also expands into medical devices and animal health sectors.

Number of Employees

571people

Average Salary

75.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

657.50Industry Average 27.710.0Point

23.7x industry avg (risky)

PBR

0.86Industry Average 1.747.0Point

Half of industry avg (excellent)

ROE

0.13Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

18.22Industry Average 6.620.0Point

2.8x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.5% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.8% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 5,260Won52-week high 8,55052-week low 4,765

1-month return0.0Point

1m -18.58% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral분기보고서 (2026.03)2026-05-15